RA CAPITAL MANAGEMENT, L.P.
Institutional investor · Portfolio as of Q4 2023
Top Holdings62 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
ASCENDIS PHARMA A/S | 10.1M | $1.3B | 19.9% | $92.74 | +35.80% | 21 qtrssince 2018-Q4 | Decreased 0 |
IMMUNOGEN INC | 23.8M | $704.2M | 11.0% | — | — | 14 qtrssince 2020-Q3 | Increased 94 |
VAXCYTE INC | 7.9M | $495.6M | 7.7% | $35.32 | +77.80% | 15 qtrssince 2020-Q2 | Unchanged 0 |
Legend Biotech Corp. Sponsored ADR | 6.3M | $376.9M | 5.9% | $58.65 | +2.59% | 6 qtrssince 2022-Q3 | Unchanged 0 |
RHYTHM PHARMACEUTICALS INC | 5.3M | $245M | 3.8% | $23.28 | +97.44% | 21 qtrssince 2018-Q4 | Decreased 0 |
| 8.3M | $187M | 2.9% | — | — | 11 qtrssince 2021-Q2 | Unchanged 0 | |
Inhibrx Biosciences, Inc. | 4.7M | $179.5M | 2.8% | — | — | 5 qtrssince 2022-Q4 | Unchanged 0 |
CYMABAY THERAPEUTICS INC | 6.9M | $163.9M | 2.6% | — | — | 2 qtrssince 2023-Q3 | Unchanged 0 |
BIOGEN IDEC INC | 532,892 | $137.9M | 2.2% | $222.99 | +16.05% | 8 qtrssince 2022-Q1 | Unchanged 0 |
RXSIGHT INC | 3.4M | $137.3M | 2.1% | $15.28 | +163.83% | 10 qtrssince 2021-Q3 | Increased 58 |
89BIO INC | 11.4M | $127.5M | 2.0% | — | — | 17 qtrssince 2019-Q4 | Unchanged 0 |
VERONA PHARMA PLC | 6.3M | $125.6M | 2.0% | — | — | 14 qtrssince 2020-Q3 | Unchanged 0 |
DAY ONE BIOPHARMACEUTICALS I | 7.8M | $114M | 1.8% | $18.91 | -22.80% | 11 qtrssince 2021-Q2 | Unchanged 0 |
AN2 THERAPEUTICS INC | 5.6M | $113.7M | 1.8% | $15.24 | +34.42% | 8 qtrssince 2022-Q1 | Unchanged 0 |
TYRA BIOSCIENCES INC | 7.2M | $100.2M | 1.6% | $16.91 | -18.10% | 10 qtrssince 2021-Q3 | Unchanged 0 |
JANUX THERAPEUTICS INC | 9.2M | $98.3M | 1.5% | $24.54 | -56.28% | 11 qtrssince 2021-Q2 | Unchanged 0 |
GERON CORP | 46.2M | $97.5M | 1.5% | $2.12 | -0.59% | 15 qtrssince 2020-Q2 | Unchanged 0 |
ICOSAVAX INC | 6M | $94M | 1.5% | — | — | 10 qtrssince 2021-Q3 | Unchanged 0 |
ALPINE IMMUNE SCIENCES INC | 4.9M | $93.6M | 1.5% | — | — | 6 qtrssince 2022-Q3 | Increased 49 |
WAVE LIFE SCIENCES LTD | 18.2M | $91.9M | 1.4% | $19.79 | -74.49% | 21 qtrssince 2018-Q4 | Increased 50 |
RA CAPITAL MANAGEMENT, L.P. manages $6.4B across 62 positions as of Q4 2023. Top holdings: ASND (19.9%), IMGN (11.0%), PCVX (7.7%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 2/5.0.
Active quarter - 5 new positions, 9 exits, 8 increased. Top move: IMGN (INCREASED, conviction 94). Portfolio: $6.4B across 62 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer